The effectiveness of lurasidone as an adjunct to lithium or divalproex in the treatment of bipolar disorder

References

• Judd LL, Akiskal HS, Schettler PJ, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002;59:530-7
   PubMed Web of Science ®Google Scholar
• Judd LL, Akiskal HS, Schettler PJ, et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry 2003;60:261-9
   PubMed Web of Science ®Google Scholar
• Vieta E, Sanchez-Moreno J, Lahuerta J, Zaragoza S; EDHIPO Group (Hypomania Detection Study Group). Subsyndromal depressive symptoms in patients with bipolar and unipolar disorder during clinical remission. J Affect Disord 2008;107:169-74
   Google Scholar
• Lloyd LC, Giaroli G, Taylor D, Tracy DK. Bipolar depression: clinically missed, pharmacologically mismanaged. Ther Adv Psychopharmacol 2011;1:153-62
   Google Scholar
• López-Muñoz F, Vieta E, Rubio G, et al. Bipolar disorder as an emerging pathology in the scientific literature: a bibliometric approach. J Affect Disord 2006;92:161-70
   PubMed Web of Science ®Google Scholar
• Gutierrez-Rojas L, Gurpegui M, Ayuso-Mateos JL, et al. Quality of life in bipolar disorder patients: a comparison with a general population sample. Bipolar Disord 2008;10:625-34
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Hirschfeld RM, Frye MA, Reed ML. Impact of depressive symptoms compared with manic symptoms in bipolar disorder: results of a US community-based sample. J Clin Psychiatry 2004;65:1499-504
   PubMed Web of Science ®Google Scholar
• Altshuler LL, Gitlin MJ, Mintz J, et al. Subsyndromal depression is associated with functional impairment in patients with bipolar disorder. J Clin Psychiatry 2002;63:807-11
   PubMed Web of Science ®Google Scholar
• Vieta E, Valenti M. Pharmacological Management of Bipolar Depression: acute Treatment, Maintenance, and Prophylaxis. CNS Drugs 2013;27:515-29
   PubMed Web of Science ®Google Scholar
• Malhi GS, Adams D, Berk M. Medicating mood with maintenance in mind: bipolar depression pharmacotherapy. Bipolar Disord 2009;11(Suppl 2):55-76
   PubMedGoogle Scholar
• Baldessarini RJ, Vieta E, Calabrese JR, et al. Bipolar depression: overview and commentary. Harv Rev Psychiatry 2010;18:143-57
   PubMed Web of Science ®Google Scholar
• Kupka RW, Altshuler LL, Nolen WA, et al. Three times more days depressed than manic or hypomanic in both bipolar I and bipolar II disorder. Bipolar Disord 2007;9:531-5
   PubMed Web of Science ®Google Scholar
• Novick DM, Swartz HA, Frank E. Suicide attempts in bipolar I and bipolar II disorder: a review and meta-analysis of the evidence. Bipolar Disord 2010;12:1-9
   PubMed Web of Science ®Google Scholar
• Kantrowitz JT, Citrome L. Lurasidone for schizophrenia: what’s different? Exp Rev Neurother 2012;12:265-73
   PubMed Web of Science ®Google Scholar
• Loebel A, Cucchiaro J, Silva R, et al. Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry 2014;171:160-8
   PubMed Web of Science ®Google Scholar
• Keck PE Jr, McElroy SL. Redefining mood stabilization. J Affect Disord 2003;73:163-9
   PubMedGoogle Scholar
• Bauer M, Ritter P, Grunze H, Pfennig A. Treatment options for acute depression in bipolar disorder. Bipolar Disord 2012;14(Suppl 2):37-50
   PubMed Web of Science ®Google Scholar
• Woo YS, Wang HR, Bahk W. Lurasidone as a potential therapy for bipolar disorder. Neuropsychiatr Dis Treat 2013;9:1521-9
   PubMed Web of Science ®Google Scholar
• Kasper S, Calabrese JR, Johnson G, et al. International Consensus Group on the Evidence-based Pharmacological Treatment of Bipolar I and II Depression. J Clin Psychiatry 2008;69:1632-46
   PubMedGoogle Scholar
• Goodwin GM. Evidence-based guidelines for treating bipolar disorder: revised second edition-recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2009;23:346-88
   PubMed Web of Science ®Google Scholar
• Yatham LN, Kennedy SH, Schaffer A, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: Update 2009. Bipolar Disord 2009;11:225-55
   PubMed Web of Science ®Google Scholar
• Grunze H, Vieta E, Goodwin GM, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: update 2010 on the treatment of acute bipolar depression. World J Biol Psychiatry 2010;11:81-109
   PubMed Web of Science ®Google Scholar
• Vieta E, Murru A, Pueyo MJ. Guia sobre el maneig del trastorn bipolar a Catalunya. Agencia d’Informació. Avaluacio i Qualitat en Salut. Servei Catala de la Salut; Barcelona, Spain: 2011
   Google Scholar
• Young AH, McElroy SL, Bauer M, et al. A double-blind, placebo controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). J Clin Psychiatry 2010;71:150-62
   PubMed Web of Science ®Google Scholar
• Geddes JR, Burgess S, Hawton K, et al. Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials. Am J Psychiatry 2004;161:217-22
   PubMed Web of Science ®Google Scholar
• Nolen WA, Weisler RH. The association of the effect of lithium in the maintenance treatment of bipolar disorder with lithium plasma levels: a post hoc analysis of a double-blind study comparing switching to lithium or placebo in patients who responded to quetiapine (Trial 144). Bipolar Disord 2013;15:100-9
   PubMed Web of Science ®Google Scholar
• Baldessarini RJ, Leahy L, Arcona S, et al. Patterns of psychotropic drug prescription for U.S. patients with diagnoses of bipolar disorders. Psychiatr Serv 2007;58:85-91
   PubMed Web of Science ®Google Scholar
• Goldberg JF, Brooks JO, Kurita K, et al. Depressive illness burden associated with complex polypharmacy in patients with bipolar disorder: findings from the STEP-BD. J Clin Psychiatry 2009;70:155-62
   PubMed Web of Science ®Google Scholar
• Sidor MM, MacQueen GM. Antidepressants for the acute treatment of bipolar depression: a systematic review and meta-analysis. J Clin Psychiatry 2010;72:156-67
   Google Scholar
• Fountoulakis KN. Pharmaceutical treatment of acute bipolar depression. F1000 Med Rep 2010;2:47-51
   Google Scholar
• Goodwin GM. Bipolar depression and treatment with antidepressants. Br J Psychiatry 2012;200:5-6
   PubMed Web of Science ®Google Scholar
• Ghaemi SN, Wingo SP, Filkowskiz MA, Baldessarini RJ. Long-term antidepressant treatment in bipolar disorder: meta-analyses of benefits and risks. Acta Psychiatr Scand 2008;118:347-56
   PubMed Web of Science ®Google Scholar
• Tondo L, Vazquez G, Baldessarini RJ. Mania associated with antidepressant treatment: comprehensive meta-analytic review. Acta Psychiatr Scand 2010;121:404-14
   PubMed Web of Science ®Google Scholar
• Leverich GS, Altshuler LL, Frye MA, et al. Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers. Am J Psychiatry 2006;163:232-9
   PubMed Web of Science ®Google Scholar
• Gijsman HJ, Geddes JR, Rendell JM, et al. Antidepressants for bipolar depression: a systematic review of randomised controlled trials. Am J Psychiatry 2004;161:1537-47
   PubMed Web of Science ®Google Scholar
• Fountoulakis KN, Vieta E, Sanchez-Moreno J, et al. Treatment guidelines for bipolar disorder: a critical review. J Affect Disord 2005;86:1-10
   PubMed Web of Science ®Google Scholar
• NICE Clinical Guidelines. Bipolar disorder. The management of bipolar disorder in adults, children and adolescents, in primary and secondary care. National Institute for Health and Clinical Excellence; London, UK: 2009
   Google Scholar
• Smith LA, Cornelius VR, Azorin JM, et al. Valproate for the treatment of acute bipolar depression: systematic review and meta-analysis. J Affect Disord 2010;122:1-9
   PubMed Web of Science ®Google Scholar
• Reinares M, Rosa AR, Franco C, et al. A systematic review on the role of anticonvulsants in the treatment of acute bipolar depression. Int J Neuropsychopharmacol 2013;16:485-96
   PubMed Web of Science ®Google Scholar
• Post RM, Uhde TW, Roy-Byrne PP, Joffe RT. Antidepressant effects of carbamazepine. Am J Psychiatry 1986;143:29-34
   PubMed Web of Science ®Google Scholar
• Zhang ZJ, Kang WH, Tan QR, et al. Adjunctive herbal medicine with carbamazepine for bipolar disorders: a double-blind, randomized, placebo-controlled study. J Psychiatr Res 2007;41:360-9
   PubMed Web of Science ®Google Scholar
• Juruena MF, Ottoni GL, Machado-Vieira R, et al. EA: Bipolar I and II disorder residual symptoms: oxcarbazepine and carbamazepine as add-on treatment to lithium in a double-blind, randomized trial. Prog Neuropsychopharmacol Biol Psychiatry 2009;33:94-9
   Google Scholar
• Chang JS, Ha K. Management of Bipolar Depression. Indian J Psychol Med 2011;33:11-17
   Google Scholar
• Geddes JR, Calabrese JR, Goodwin GM. Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials. Br J Psychiatry 2009;194:4-9
   PubMed Web of Science ®Google Scholar
• Rubio G, López-Muñoz F, Álamo C. Effects of lamotrigine in patients with bipolar disorder and alcohol dependence. Bipolar Disord 2006;8:289-93
   PubMedGoogle Scholar
• Van der Loos ML, Mulder PG, Hartong EG, et al. Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: a multicenter, double-blind, placebo-controlled trial. J Clin Psychiatry 2009;70:223-31
   PubMed Web of Science ®Google Scholar
• Zarate CA Jr, Tohen M. Double-blind comparison of the continued use of antipsychotic treatment versus its discontinuation in remitted manic patients. Am J Psychiatry 2004;161:169-71
   PubMed Web of Science ®Google Scholar
• López-Muñoz F, Shen WW, Moreno R, et al. International scientific productivity on second-generation antipsychotic drugs in Taiwan: a bibliometric study. Taiwanese J Psychiatry 2012;26:114-29
   Google Scholar
• López-Muñoz F, Shinfuku N, Shen WW, et al. Thirty years of scientific research on second-generation antipsychotic drugs in Japan: a bibliometric analysis. Open J Psychiatry 2013;3:18-25
   Google Scholar
• López-Muñoz F, Shen WW, Pae CU, et al. Trends in scientific literature on atypical antipsychotics in South Korea: a bibliometric study. Psychiatry Investig 2013;10:8-16
   Google Scholar
• López-Muñoz F, Castle DJ, Shen WW, et al. The Australian contribution to the literature on atypical antipsychotic drugs: a bibliometric study. Australas Psychiatry 2013;21:343-5
   PubMed Web of Science ®Google Scholar
• López-Muñoz F, Rubio G, Molina JD, et al. Mapping the scientific research on atypical antipsychotic drugs in Spain: a bibliometric assessment. Actas Esp Psiquiatr 2013;41:349-60
   PubMed Web of Science ®Google Scholar
• Grande I, Bernardo M, Bobes J, et al. Antipsychotic switching in bipolar disorders: a systematic review. Int J Neuropsychopharmacol 2014;17:497-507
   PubMed Web of Science ®Google Scholar
• Cruz N, Sanchez-Moreno J, Torres F, et al. Efficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysis. Int J Neuropsychopharmacol 2013;13:5-14
   Google Scholar
• De Fruyt J, Deschepper E, Audenaert K, et al. Second generation antipsychotics in the treatment of bipolar depression: a systematic review and meta-analysis. J Psychopharmacol 2012;26:603-17
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Cha DS, Kim RD, Mansur RB. A review of FDA-approved treatment options in bipolar depression. CNS Spectr 2013;18(Suppl 1):1-21
   Google Scholar
• Álamo C, Lopez-Muñoz F. Eficacia de quetiapina de liberación prolongada en la sintomatología afectiva. Rev Psiquiatr Salud Ment (Barc) 2012;5(Suppl 1):3-19
   Google Scholar
• Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003;60:1079-88
   PubMed Web of Science ®Google Scholar
• Zhang H, Wang H, Zhu X, et al. Lurasidone hydro-chloride. Acta Crystallogr Sect E Struct Rep Online 2012;68(Pt. 5):o1357
   Google Scholar
• Ishibashi T, Horisawa T, Tokuda K, et al. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J Pharmacol Exp Ther 2010;334:171-81
   PubMed Web of Science ®Google Scholar
• Wong DF, Kuwabara H, Brašić JR, et al. Determination of dopamine D2 receptor occupancy by lurasidone using positron emission tomography in healthy male subjects. Psychopharmacology (Berl) 2013;229:245-52
   Web of Science ®Google Scholar
• Newman-Tancredi A, Kleven MS. Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties. Psychopharmacology (Berl) 2011;216:451-73
   PubMed Web of Science ®Google Scholar
• Caccia S, Pasina L, Nobili A. Critical appraisal of lurasidone in the management of schizophrenia. Neuropsychiatr Dis Treat 2012;8:155-68
   PubMed Web of Science ®Google Scholar
• Meneses A. Effects of the 5-HT7 receptor antagonists SB-269970 and DR 4004 in autoshaping Pavlovian/instrumental learning task. Behav Brain Res 2004;155:275-82
   PubMed Web of Science ®Google Scholar
• Enomoto T, Ishibashi T, Tokuda K, et al. Lurasidone reverses MK-801-induced impairment of learning and memory in the Morris water maze and radial-arm maze test in rats. Behav Brain Res 2008;186:197-207
   PubMed Web of Science ®Google Scholar
• Hedlund PB, Huitron-Resendiz S, Henriksen SJ, Sutcliffe JG. 5-HT7 receptor inhibition and inactivation induce antidepressant like behaviour and sleep pattern. Biol Psychiatry 2005;58:831-7
   PubMed Web of Science ®Google Scholar
• Wesołowska A, Nikiforuk A, Stachowicz K, Tatarczynska E. Effect of the selective 5-HT7 receptor antagonist SB 269970 in animal models of anxiety and depression. Neuropharmacology 2006;51:578-86
   PubMed Web of Science ®Google Scholar
• Sallinen J, Hoglund I, Engstrom M, et al. Pharmacological characterization and CNS effects of a novel highly selective alpha-2C-adrenoceptors antagonist JP-1302. Br J Pharmacol 2007;150:391-402
   PubMed Web of Science ®Google Scholar
• Terry AV Jr, Mahadik SP. Time-dependent cognitive deficits associated with first and second generation antipsychotics: cholinergic dysregulation as a potential mechanism. J Pharmacol Exp Ther 2007;320:961-8
   PubMedGoogle Scholar
• Reynolds GP, Hill MJ, Kirk SL. The 5-HT2C receptor and antipsychotic induced weight gain – mechanisms and genetics. J Psychopharmacol 2006;20:15-18
   PubMedGoogle Scholar
• Kroeze WK, Hufeisen SJ, Popadak BA, et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 2003;28:519-26
   PubMed Web of Science ®Google Scholar
• Horiguchi M, Huang M, Meltzer HY. The role of 5-hydroxytryptamine 7 receptors in the phencyclidine-induced novel object recognition deficit in rats. J Pharmacol Exp Ther 2011;338:605-14
   PubMed Web of Science ®Google Scholar
• Haddad P. Weight change with atypical antipsychotics in the treatment of schizophrenia. J Psychopharmacol 2005;19:16-27
   PubMedGoogle Scholar
• Preskorn S, Chiu YY, Sarubbi D, et al. Lurasidone pharmacokinetics: assessment of potential for drug–drug interactions. Neuropsychopharmacology 2010;35(Suppl 1):395
   Google Scholar
• Caccia S. Pharmacokinetics and metabolism update for some recent antipsychotics. Expert Opin Drug Metab Toxicol 2011;7:829-46
   PubMed Web of Science ®Google Scholar
• Meyer JM, Loebel AD, Schweizer E. Lurasidone: a new drug in development for schizophrenia. Expert Opin Investig Drugs 2009;18:1715-26
   PubMed Web of Science ®Google Scholar
• Citrome L. Lurasidone for schizophrenia: a brief review of a new second-generation antipsychotic. Clin Schizophr Relat Psychoses 2011;4:251-7
   PubMedGoogle Scholar
• Guay DR. Comment on the potential utility of the new atypical antipsychotic lurasidone in the geriatric population. Consult Pharm 2011;26:579-82
   PubMedGoogle Scholar
• Citrome L, Ketter TA, Cucchiaro J, Loebel A. Clinical assessment of lurasidone benefit and risk in the treatment of bipolar I depression using number needed to treat, number needed to harm, and likelihood to be helped or harmed. J Affect Disord 2014;155:20-7
   PubMed Web of Science ®Google Scholar
• Citrome L, Weiden PJ, McEvoy JP, et al. A Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: a 6-month, open-label, extension study. CNS Spectr 2013;16:1-10
   Google Scholar
• Van Lieshout RJ, MacQueen GM. Efficacy and acceptability of mood stabilisers in the treatment of acute bipolar depression: systematic review. Br J Psychiatry 2010;196:266-73
   PubMed Web of Science ®Google Scholar
• Sachs GS, Ice KS, Chappell PB, et al. Efficacy and safety of adjunctive oral ziprasidone for acute treatment of depression in patients with bipolar I disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2011;72:1413-22
   PubMed Web of Science ®Google Scholar
• Loebel A, Cucchiaro J, Silva R, et al. Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry 2014;171:169-77
   PubMed Web of Science ®Google Scholar
• Lombardo I, Sachs G, Kolluri S, et al. Two 6-week, randomized, double-blind, placebo-controlled studies of ziprasidone in out-patients with bipolar I depression: did baseline characteristics impact trial outcome? J Clin Psychopharmacol 2012;32:470-8
   PubMed Web of Science ®Google Scholar
• Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord 2013;15:1-44
   PubMed Web of Science ®Google Scholar
• Belmaker RH. Lurasidone and Bipolar Disorder. Am J Psychiatry 2014;171:131-3
   Google Scholar